Telomir Pharmaceuticals, Inc.
TELO· Nasdaq
TELOTelomir Pharmaceuticals, Inc.
Filed May 14, 2026 · 10-Q · 44 days after period end · 0001493152-26-023010
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Net Income | -$990.95K | -$2.18M | -$6.25M | -$482.94K |
| EPS Diluted | -$0.03 | -$0.07 | -$0.23 | -$0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Telomir Pharmaceuticals, Inc. · CIK 1971532 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 14, 2026 · 44 d after period end
